Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01734785 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
NCT01734785 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 607 participants.
The verdict
NCT01734785, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
Study Summary
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
Interventions
- DRUG Linagliptin
- DRUG Empagliflozin + Linagliptin
- DRUG Empagliflozin placebo + Linagliptin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2013-02-08 |
| Est. Completion | 2015-03-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01734785
The ClinicalTrials.gov registry entry for NCT01734785 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Linagliptin is the first listed.
NCT01734785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01734785 about?
NCT01734785 is a clinical study titled "Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes". This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
What is the current status of trial NCT01734785?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2013-02-08. Estimated completion is 2015-03-23.
What interventions are being tested in trial NCT01734785?
The interventions under investigation include: Linagliptin (DRUG), Empagliflozin + Linagliptin (DRUG), Empagliflozin placebo + Linagliptin placebo (DRUG).
Who is sponsoring clinical trial NCT01734785?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.